[{"id":"b3aaeb0c-f80e-4dde-8c61-c9b49da33a02","acronym":"","url":"https://clinicaltrials.gov/study/NCT07207707","created_at":"2025-10-11T01:26:49.129Z","updated_at":"2025-10-11T01:26:49.129Z","phase":"Phase 1","brief_title":"A Study to Investigate the Safety and Efficacy of KQB548 in Participants With Advanced Solid Malignancies","source_id_and_acronym":"NCT07207707","lead_sponsor":"Kumquat Biosciences Inc.","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"],"overall_status":"Recruiting","enrollment":" Enrollment 78","initiation":"Initiation: 09/16/2025","start_date":" 09/16/2025","primary_txt":" Primary completion: 09/01/2026","primary_completion_date":" 09/01/2026","study_txt":" Completion: 03/01/2027","study_completion_date":" 03/01/2027","last_update_posted":"2025-10-06"},{"id":"0e00e05b-2578-4acd-967c-8c5eb860f4a0","acronym":"","url":"https://clinicaltrials.gov/study/NCT07026916","created_at":"2025-06-21T13:17:33.061Z","updated_at":"2025-06-21T13:17:33.061Z","phase":"Phase 2","brief_title":"A Phase II Study to Evaluate GFH375 in Patients With KRAS G12D Mutant Metastatic Pancreatic Cancer","source_id_and_acronym":"NCT07026916","lead_sponsor":"Genfleet Therapeutics (Shanghai) Inc.","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 83","initiation":"Initiation: 08/01/2025","start_date":" 08/01/2025","primary_txt":" Primary completion: 12/01/2027","primary_completion_date":" 12/01/2027","study_txt":" Completion: 08/01/2028","study_completion_date":" 08/01/2028","last_update_posted":"2025-06-18"},{"id":"b0c3d0f3-340f-42f7-821e-d51795e6563a","acronym":"","url":"https://clinicaltrials.gov/study/NCT07020221","created_at":"2025-06-14T13:52:20.544Z","updated_at":"2025-06-14T13:52:20.544Z","phase":"Phase 1/2","brief_title":"A Phase 1/2a Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors","source_id_and_acronym":"NCT07020221","lead_sponsor":"Verastem, Inc.","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 130","initiation":"Initiation: 06/01/2025","start_date":" 06/01/2025","primary_txt":" Primary completion: 09/01/2028","primary_completion_date":" 09/01/2028","study_txt":" Completion: 09/01/2028","study_completion_date":" 09/01/2028","last_update_posted":"2025-06-13"},{"id":"9fb2cdde-012a-4d53-b589-d932fba3f768","acronym":"C2025-009-01","url":"https://clinicaltrials.gov/study/NCT07014878","created_at":"2025-06-14T13:55:09.580Z","updated_at":"2025-06-14T13:55:09.580Z","phase":"Phase 1","brief_title":"A Study of DCTY1102 Injection in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT07014878 - C2025-009-01","lead_sponsor":"Beijing DCTY Biotech Co.,Ltd.","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 110","initiation":"Initiation: 06/01/2025","start_date":" 06/01/2025","primary_txt":" Primary completion: 05/01/2028","primary_completion_date":" 05/01/2028","study_txt":" Completion: 05/01/2028","study_completion_date":" 05/01/2028","last_update_posted":"2025-06-11"},{"id":"297cd590-bacb-40d9-b395-eacfa8bc49d5","acronym":"","url":"https://clinicaltrials.gov/study/NCT06949761","created_at":"2025-09-07T01:25:54.516Z","updated_at":"2025-09-07T01:25:54.516Z","phase":"Phase 1/2","brief_title":"A Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of QLC1101 in Combination With Other Therapies in the Treatment of Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation","source_id_and_acronym":"NCT06949761","lead_sponsor":"Qilu Pharmaceutical Co., Ltd.","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • docetaxel • Qibeian (iparomlimab/tuvonralimab) • QL1203"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 240","initiation":"Initiation: 06/01/2025","start_date":" 06/01/2025","primary_txt":" Primary completion: 09/01/2026","primary_completion_date":" 09/01/2026","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2025-04-29"},{"id":"71a4afcd-6df8-4c91-9a29-c1843f5eade5","acronym":"","url":"https://clinicaltrials.gov/study/NCT06179160","created_at":"2023-12-21T15:19:06.393Z","updated_at":"2025-02-25T13:50:04.432Z","phase":"Phase 1","brief_title":"A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation","source_id_and_acronym":"NCT06179160","lead_sponsor":"Incyte Corporation","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • irinotecan • Zynyz (retifanlimab-dlwr)"],"overall_status":"Recruiting","enrollment":" Enrollment 466","initiation":"Initiation: 01/04/2024","start_date":" 01/04/2024","primary_txt":" Primary completion: 01/01/2027","primary_completion_date":" 01/01/2027","study_txt":" Completion: 01/01/2027","study_completion_date":" 01/01/2027","last_update_posted":"2025-02-21"},{"id":"356b44d6-dd58-4331-be47-3289089beb92","acronym":"ALAFOSS-01","url":"https://clinicaltrials.gov/study/NCT06599502","created_at":"2025-02-25T13:56:50.654Z","updated_at":"2025-02-25T13:56:50.654Z","phase":"Phase 1/2","brief_title":"A Phase I/IIa Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD0022 as Monotherapy and in Combination With Anti-cancer Agents in Adult Participants With Tumours Harbouring a KRASG12D Mutation","source_id_and_acronym":"NCT06599502 - ALAFOSS-01","lead_sponsor":"AstraZeneca","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12D","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12D"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab)"],"overall_status":"Recruiting","enrollment":" Enrollment 430","initiation":"Initiation: 10/18/2024","start_date":" 10/18/2024","primary_txt":" Primary completion: 01/20/2028","primary_completion_date":" 01/20/2028","study_txt":" Completion: 01/20/2028","study_completion_date":" 01/20/2028","last_update_posted":"2025-02-20"},{"id":"423b6342-3f3c-493a-8e38-416828c5870d","acronym":"","url":"https://clinicaltrials.gov/study/NCT06500676","created_at":"2025-02-25T15:45:43.137Z","updated_at":"2025-02-25T15:45:43.137Z","phase":"Phase 1/2","brief_title":"A Study of GFH375 in Patients with Advanced Solid Tumors with KRAS G12D Mutations","source_id_and_acronym":"NCT06500676","lead_sponsor":"Genfleet Therapeutics (Shanghai) Inc.","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"],"overall_status":"Recruiting","enrollment":" Enrollment 290","initiation":"Initiation: 07/09/2024","start_date":" 07/09/2024","primary_txt":" Primary completion: 07/31/2028","primary_completion_date":" 07/31/2028","study_txt":" Completion: 12/31/2028","study_completion_date":" 12/31/2028","last_update_posted":"2025-02-11"},{"id":"04b23f96-640c-4d7c-9c86-475db9834138","acronym":"","url":"https://clinicaltrials.gov/study/NCT06428500","created_at":"2024-05-25T04:08:06.513Z","updated_at":"2025-02-25T15:29:03.721Z","phase":"Phase 1","brief_title":"QTX3046 in Patients with KRAS G12D Mutations","source_id_and_acronym":"NCT06428500","lead_sponsor":"Quanta Therapeutics","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • QTX3046"],"overall_status":"Recruiting","enrollment":" Enrollment 240","initiation":"Initiation: 05/30/2024","start_date":" 05/30/2024","primary_txt":" Primary completion: 07/01/2027","primary_completion_date":" 07/01/2027","study_txt":" Completion: 07/01/2027","study_completion_date":" 07/01/2027","last_update_posted":"2025-02-10"},{"id":"dbe82f72-f4ab-4023-bd80-f4e491e396d7","acronym":"","url":"https://clinicaltrials.gov/study/NCT06619587","created_at":"2025-02-25T16:48:28.168Z","updated_at":"2025-02-25T16:48:28.168Z","phase":"Phase 1","brief_title":"A Study to Evaluate Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT06619587","lead_sponsor":"Genentech, Inc.","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"],"overall_status":"Recruiting","enrollment":" Enrollment 410","initiation":"Initiation: 11/14/2024","start_date":" 11/14/2024","primary_txt":" Primary completion: 11/30/2028","primary_completion_date":" 11/30/2028","study_txt":" Completion: 11/30/2028","study_completion_date":" 11/30/2028","last_update_posted":"2025-02-05"},{"id":"36a30724-fb72-46bb-a2d8-e449e2bbfcf4","acronym":"MOONRAY-01","url":"https://clinicaltrials.gov/study/NCT06586515","created_at":"2025-02-25T18:00:11.905Z","updated_at":"2025-02-25T18:00:11.905Z","phase":"Phase 1","brief_title":"A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors","source_id_and_acronym":"NCT06586515 - MOONRAY-01","lead_sponsor":"Eli Lilly and Company","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • gemcitabine • 5-fluorouracil • albumin-bound paclitaxel • oxaliplatin • irinotecan • leucovorin calcium"],"overall_status":"Recruiting","enrollment":" Enrollment 530","initiation":"Initiation: 09/12/2024","start_date":" 09/12/2024","primary_txt":" Primary completion: 03/01/2029","primary_completion_date":" 03/01/2029","study_txt":" Completion: 03/01/2029","study_completion_date":" 03/01/2029","last_update_posted":"2025-01-28"},{"id":"ace74252-54a3-493a-b223-6a52f7db4913","acronym":"","url":"https://clinicaltrials.gov/study/NCT06770452","created_at":"2025-02-26T06:54:41.243Z","updated_at":"2025-02-26T06:54:41.243Z","phase":"Phase 2","brief_title":"HRS-4642 with Nimotuzumab and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer Patients","source_id_and_acronym":"NCT06770452","lead_sponsor":"Zhejiang University","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • albumin-bound paclitaxel • TheraCIM (nimotuzumab) • HRS-4642"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 02/01/2025","start_date":" 02/01/2025","primary_txt":" Primary completion: 02/01/2027","primary_completion_date":" 02/01/2027","study_txt":" Completion: 02/01/2028","study_completion_date":" 02/01/2028","last_update_posted":"2025-01-13"},{"id":"97072759-d618-48d0-b29e-295d8bf2e9f2","acronym":"TRIAD1","url":"https://clinicaltrials.gov/study/NCT06667544","created_at":"2025-02-26T11:55:40.746Z","updated_at":"2025-02-26T11:55:40.746Z","phase":"Phase 1/2","brief_title":"A Study of RNK08954 in Subjects With Advanced Solid Tumors With KRAS ((Kirsten Rat Sarcoma) G12D Mutation","source_id_and_acronym":"NCT06667544 - TRIAD1","lead_sponsor":"Ranok Therapeutics (Hangzhou) Co., Ltd.","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12D","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12D"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 152","initiation":"Initiation: 12/01/2024","start_date":" 12/01/2024","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 07/01/2027","study_completion_date":" 07/01/2027","last_update_posted":"2024-10-31"},{"id":"88bf7c40-1a30-459a-8693-a4d5d65c020b","acronym":"","url":"https://clinicaltrials.gov/study/NCT06587061","created_at":"2025-02-26T14:52:08.919Z","updated_at":"2025-02-26T14:52:08.919Z","phase":"Phase 2","brief_title":"HRS-4642 in Combination With AG for Neoadjuvant and Adjuvant Treatment of Pancreatic Cancer","source_id_and_acronym":"NCT06587061","lead_sponsor":"Ruijin Hospital","biomarkers":" CA 19-9","pipe":"","alterations":" ","tags":["CA 19-9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • albumin-bound paclitaxel • HRS-4642"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 10/01/2024","start_date":" 10/01/2024","primary_txt":" Primary completion: 06/01/2027","primary_completion_date":" 06/01/2027","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2024-09-19"},{"id":"d026d8e4-9c91-4cee-be37-7c17094bbad4","acronym":"","url":"https://clinicaltrials.gov/study/NCT06218914","created_at":"2024-01-23T17:20:10.961Z","updated_at":"2024-07-02T16:34:25.951Z","phase":"Phase 1","brief_title":"A Study of NT-112 in HLA-C*08:02-Positive Adult Subjects With Unresectable, Advanced, and/ or Metastatic Solid Tumors Positive for the KRAS G12D Mutation","source_id_and_acronym":"NCT06218914","lead_sponsor":"Neogene Therapeutics, Inc.","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 02/05/2024","start_date":" 02/05/2024","primary_txt":" Primary completion: 08/30/2025","primary_completion_date":" 08/30/2025","study_txt":" Completion: 01/02/2040","study_completion_date":" 01/02/2040","last_update_posted":"2024-06-14"},{"id":"b7624b27-8c4e-4193-bab7-2c294ff4563f","acronym":"","url":"https://clinicaltrials.gov/study/NCT06385925","created_at":"2024-04-26T14:50:24.450Z","updated_at":"2024-07-02T16:34:37.904Z","phase":"Phase 1/2","brief_title":"A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation","source_id_and_acronym":"NCT06385925","lead_sponsor":"Tyligand Bioscience (Shanghai) Limited","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12D","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12D"],"overall_status":"Recruiting","enrollment":" Enrollment 150","initiation":"Initiation: 04/29/2024","start_date":" 04/29/2024","primary_txt":" Primary completion: 10/30/2026","primary_completion_date":" 10/30/2026","study_txt":" Completion: 04/30/2027","study_completion_date":" 04/30/2027","last_update_posted":"2024-06-06"},{"id":"8d686149-a583-41f2-8927-e211fb3a2fb7","acronym":"QTX3034-001","url":"https://clinicaltrials.gov/study/NCT06227377","created_at":"2024-01-26T18:20:28.721Z","updated_at":"2024-07-02T16:35:00.369Z","phase":"Phase 1","brief_title":"QTX3034 in Patients With KRAS G12D Mutation","source_id_and_acronym":"NCT06227377 - QTX3034-001","lead_sponsor":"Quanta Therapeutics","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • QTX3034"],"overall_status":"Recruiting","enrollment":" Enrollment 250","initiation":"Initiation: 02/05/2024","start_date":" 02/05/2024","primary_txt":" Primary completion: 04/01/2027","primary_completion_date":" 04/01/2027","study_txt":" Completion: 04/01/2027","study_completion_date":" 04/01/2027","last_update_posted":"2024-05-29"},{"id":"a4ae9962-83f6-4e21-b02b-394d2caf5c4f","acronym":"QLC1101-101","url":"https://clinicaltrials.gov/study/NCT06403735","created_at":"2024-05-11T04:24:16.762Z","updated_at":"2024-07-02T16:35:05.042Z","phase":"Phase 1","brief_title":"A Phase I Clinical Study of QLC1101 in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT06403735 - QLC1101-101","lead_sponsor":"Qilu Pharmaceutical Co., Ltd.","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"],"overall_status":"Recruiting","enrollment":" Enrollment 250","initiation":"Initiation: 04/25/2024","start_date":" 04/25/2024","primary_txt":" Primary completion: 05/31/2026","primary_completion_date":" 05/31/2026","study_txt":" Completion: 04/30/2027","study_completion_date":" 04/30/2027","last_update_posted":"2024-05-08"},{"id":"6ca81930-eac3-48d7-bbb1-3b7c3ad88e89","acronym":"","url":"https://clinicaltrials.gov/study/NCT06364696","created_at":"2024-04-15T18:25:41.171Z","updated_at":"2024-07-02T16:35:07.144Z","phase":"Phase 1","brief_title":"A Study to Find a Suitable Dose of ASP4396 in Adults With Solid Tumors","source_id_and_acronym":"NCT06364696","lead_sponsor":"Astellas Pharma Inc","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"],"overall_status":"Recruiting","enrollment":" Enrollment 175","initiation":"Initiation: 04/16/2024","start_date":" 04/16/2024","primary_txt":" Primary completion: 04/30/2027","primary_completion_date":" 04/30/2027","study_txt":" Completion: 04/30/2027","study_completion_date":" 04/30/2027","last_update_posted":"2024-04-29"},{"id":"07acdaee-81fa-42a2-b6a8-44ffa1343ca1","acronym":"","url":"https://clinicaltrials.gov/study/NCT06385678","created_at":"2024-04-26T18:53:22.008Z","updated_at":"2024-07-02T16:35:07.335Z","phase":"Phase 1/2","brief_title":"A Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation","source_id_and_acronym":"NCT06385678","lead_sponsor":"Jiangsu HengRui Medicine Co., Ltd.","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • pemetrexed • AiRuiLi (adebrelimab) • HRS-4642 • tizetatug rezetecan (SHR-A1921)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 05/01/2024","start_date":" 05/01/2024","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 08/01/2026","study_completion_date":" 08/01/2026","last_update_posted":"2024-04-26"},{"id":"fe61047d-8ed4-4b77-a9be-8df7e1bcb409","acronym":"","url":"https://clinicaltrials.gov/study/NCT06040541","created_at":"2023-09-15T18:10:24.393Z","updated_at":"2024-07-02T16:35:21.224Z","phase":"Phase 1","brief_title":"Study of RMC-9805 in Participants With KRASG12D-Mutant Solid Tumors","source_id_and_acronym":"NCT06040541","lead_sponsor":"Revolution Medicines, Inc.","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12D • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12D • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e zoldonrasib (RMC-9805)"],"overall_status":"Recruiting","enrollment":" Enrollment 290","initiation":"Initiation: 09/07/2023","start_date":" 09/07/2023","primary_txt":" Primary completion: 08/30/2025","primary_completion_date":" 08/30/2025","study_txt":" Completion: 07/31/2026","study_completion_date":" 07/31/2026","last_update_posted":"2024-02-01"},{"id":"84bcb047-48bf-41ab-8d01-d2bc5efa22fb","acronym":"","url":"https://clinicaltrials.gov/study/NCT05737706","created_at":"2023-02-21T15:01:29.871Z","updated_at":"2024-07-02T16:35:28.495Z","phase":"Phase 1/2","brief_title":"Study of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation","source_id_and_acronym":"NCT05737706","lead_sponsor":"Mirati Therapeutics Inc.","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12D • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12D • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MRTX1133"],"overall_status":"Recruiting","enrollment":" Enrollment 386","initiation":"Initiation: 03/20/2023","start_date":" 03/20/2023","primary_txt":" Primary completion: 08/30/2026","primary_completion_date":" 08/30/2026","study_txt":" Completion: 08/30/2026","study_completion_date":" 08/30/2026","last_update_posted":"2023-11-21"},{"id":"b981fcae-ee9d-4262-ac3e-1cf908d11d83","acronym":"","url":"https://clinicaltrials.gov/study/NCT05533463","created_at":"2022-09-09T15:54:57.974Z","updated_at":"2024-07-02T16:35:30.238Z","phase":"Phase 1","brief_title":"Phase I Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation","source_id_and_acronym":"NCT05533463","lead_sponsor":"Jiangsu HengRui Medicine Co., Ltd.","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12D • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12D • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HRS-4642"],"overall_status":"Recruiting","enrollment":" Enrollment 108","initiation":"Initiation: 09/15/2022","start_date":" 09/15/2022","primary_txt":" Primary completion: 04/30/2024","primary_completion_date":" 04/30/2024","study_txt":" Completion: 12/30/2024","study_completion_date":" 12/30/2024","last_update_posted":"2023-11-06"},{"id":"c588db17-efc8-49b9-af67-a28b72dc4313","acronym":"","url":"https://clinicaltrials.gov/study/NCT06096974","created_at":"2023-10-24T15:13:42.150Z","updated_at":"2024-07-02T16:35:31.995Z","phase":"Phase 1","brief_title":"Pan-RAS Inhibitor YL-17231 in Patients With Advanced Solid Tumors Harboring Mutations in KRAS, HRAS, or NRAS","source_id_and_acronym":"NCT06096974","lead_sponsor":"Shanghai YingLi Pharmaceutical Co. Ltd.","biomarkers":" PD-L1 • KRAS • NRAS • HRAS","pipe":" | ","alterations":" KRAS mutation • NRAS mutation • HRAS mutation","tags":["PD-L1 • KRAS • NRAS • HRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • NRAS mutation • HRAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e YL-17231"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 10/01/2023","start_date":" 10/01/2023","primary_txt":" Primary completion: 04/01/2025","primary_completion_date":" 04/01/2025","study_txt":" Completion: 04/01/2026","study_completion_date":" 04/01/2026","last_update_posted":"2023-10-24"}]